Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Osteoporos Int ; 31(3): 447-455, 2020 Mar.
Article in English | MEDLINE | ID: mdl-31838553

ABSTRACT

Patients with diabetes have an increased risk of fractures. In this study, subtrochanteric and femoral shaft fractures were increased in patients with type 1 diabetes compared with the general population. In the light of this, more evidence points towards an association between diabetes and atypical femoral fractures. INTRODUCTION: Patients with diabetes have an increased risk of femoral fractures, but little is known about the risk of atypical femoral fractures (AFFs). The aim of this study was to identify the risk of subtrochanteric and femoral shaft (ST/FS) fractures and estimate the risk of AFFs in patients with type 1 (T1D) and type 2 diabetes (T2D). METHODS: From the nationwide Danish National Patient Register, we identified patients with T1D (n = 19,896), T2D (n = 312,188), and sex- and aged-matched controls without diabetes (n = 996,252) from the general population and all ST/FS fractures (n = 7509). Data were analyzed using a Cox proportional-hazards model and the incidence rate and rate ratio of ST/FS fractures were estimated. RESULTS: The incidence rate of ST/FS fractures in T1D was 52.14 events per 100,000 person years and 73.21 per 100,000 person years in T2D. T1D was associated with an increased risk of ST/FS (HR 2.07 (95% CI 1.68-2.56)), whereas T2D was not (HR 0.99 (95% CI 0.94-1.10)). Previous ST/FS fractures were associated with an increased risk of subsequent ST/FS fractures (HR 6.95 (95% CI 6.00-8.05)) and the use of bisphosphonates with an increased risk of ST/FS fractures (HR 1.72 (95% CI 1.54-1.91)). CONCLUSION: Patients with T1D have a higher risk of ST/FS fractures compared with sex- and age-matched controls. Since a proportion of ST/FS fractures are classified as AFFs, this could point towards the fact that AFFs also are increased in patients with T1D, but not T2D.


Subject(s)
Diabetes Mellitus, Type 2 , Femoral Fractures , Hip Fractures , Osteoporosis , Aged , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/epidemiology , Diphosphonates , Female , Femoral Fractures/epidemiology , Femoral Fractures/etiology , Hip Fractures/epidemiology , Hip Fractures/etiology , Humans , Incidence , Male
2.
Eur J Endocrinol ; 174(5): 663-7, 2016 May.
Article in English | MEDLINE | ID: mdl-26903550

ABSTRACT

CONTEXT: Although combination therapy of acromegaly with long-acting somatostatin analogs (LA-SSAs) and pegvisomant (PEGV) normalizes insulin-like growth factor-1 (IGF1) levels in the majority of patients, it requires long-term adherence. Switching from combination therapy to monotherapy with weekly PEGV could improve patients' comfort, but the efficacy is unknown. OBJECTIVE: To assess the efficacy of switching to PEGV monotherapy in patients well controlled on combination therapy of LA-SSAs and PEGV. DESIGN: Single-center, open-label observational pilot study. LA-SSA therapy was discontinued at baseline and all patients were switched to PEGV monotherapy for 12 months. If IGF1 levels exceeded 1.0 times upper limit of normal (ULN), PEGV dose was increased by 20 mg weekly. SUBJECTS AND METHODS: The study included 15 subjects (eight males), with a median age of 58 years (range 35-80) on combination therapy of high-dose LA-SSAs and weekly PEGV for >6 months, and IGF1 levels within the normal range. Treatment efficacy was assessed by measuring serum IGF1 levels. RESULTS: After 12 months of weekly PEGV monotherapy, serum IGF1 levels of 73% of the subjects remained controlled. In one patient, LA-SSA had to be restarted due to recurrence of headache. IGF1 levels increased from a baseline level of 0.62 × ULN (range 0.30-0.84) to 0.83 × ULN (0.30-1.75) after 12 months, while the median weekly PEGV dose increased from 60 (30-80) mg to 80 (50-120) mg. CONCLUSION: Our results suggest that switching from combination therapy of LA-SSAs and PEGV to PEGV monotherapy can be a viable treatment option for acromegaly patients without compromising efficacy.


Subject(s)
Acromegaly/blood , Acromegaly/drug therapy , Human Growth Hormone/analogs & derivatives , Insulin-Like Growth Factor I/analysis , Outcome Assessment, Health Care , Somatostatin/pharmacology , Adult , Aged , Aged, 80 and over , Drug Therapy, Combination , Female , Human Growth Hormone/administration & dosage , Human Growth Hormone/pharmacology , Humans , Male , Middle Aged , Pilot Projects , Somatostatin/administration & dosage , Somatostatin/analogs & derivatives
3.
Vet Parasitol ; 16(1-2): 17-22, 1984 Oct.
Article in English | MEDLINE | ID: mdl-6543049

ABSTRACT

Serum samples were obtained from pigs originating from specified pathogen-free farms, large industrialised farms and small conventional farms. All animals proved to be free of Trichinella spiralis by a pooled sample digestion method. Careful meat inspection studies on parasitic infections other than trichinellosis, and other inflammatory reactions were recorded and used for subdivision of the animals in different groups. It was concluded that animal husbandry, parasitic infections, or inflammatory reactions have not influenced the mean extinction values of an ELISA for the detection of T. spiralis antibodies, however, the specified pathogen free animals yielded somewhat lower results.


Subject(s)
Antibodies/analysis , Swine Diseases/diagnosis , Trichinella/immunology , Trichinellosis/veterinary , Animal Husbandry/methods , Animals , Denmark , Enzyme-Linked Immunosorbent Assay , Food Inspection , Meat , Swine/parasitology , Trichinellosis/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL
...